A clinical observative study concerning Celebrex administration impact on serological inflammatory factor, skin temperature and knee function after total knee arthroplasty

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-ONRC-13003785

Enrollment

Unknown

Registered

2013-10-29

Start date

2013-11-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

knee osteoarthritis

Interventions

A:Tramadol hydrochloride sustained release tablets

B:celecoxib capsule

Eligibility

Sex/Gender

All

Age

50 Years to 80 Years

Inclusion criteria

Inclusion criteria: From July 1, 2013 to August 1, 2014, patients who underwen primary total knee arthroplasty range from 50 to 80 years old.

Exclusion criteria

Exclusion criteria: 1. patients older than 80 years; 2. patients with hypertension, congestive heart failure and other cardiovascular diseases who are taking diuretics, ACE inhibitors and angiotensin II antagonist; 3. patients with gastric ulcer; 4. patients who are taking warfarin; 5. patients with impaired liver function; 6. patients with advanced kidney disease; 7. patients with acute kidney injury; 8. patients who are ellergic with sulfanilamide or tramadol drug; 9. patients with familial adenomatous polyposis; 10. patients with fractures in acute stage; 11. patients with delirium and dementia or those who can not obtain informed consent; 12. patients who are taking part in other clinical trials; 13. other reasons wha are not suitable for clinical trial.

Design outcomes

Primary

Measure	Time frame
knee temperature;white blood cells;C-reactive protein;erythrocyte sedimentation rate;	—

Contacts

Public ContactYirong ZENG

zeng6612@163.com+86 13711456292

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026